22 Nov 2022 - Radiopharm Theranostics Limited (ASX:RAD) Managing Director and CEO Riccardo Canevari discusses the progress of the company's brain, lung and prostate cancer therapies.

17 Nov 2022 - Genetic Signatures Limited (ASX:GSS) CEO and Director Dr John Melki discusses the company's technology, business model, 2022 highlights and outlook.

15 Nov 2022 - Arovella Therapeutics Limited (ASX:ALA) Managing Director and CEO Dr Michael Baker provides an update on the company.

15 Nov 2022 - OncoSil Medical Limited (ASX:OSL) Non-Executive Director Brian Leedman discusses joining the board of OncoSil and receiving CE mark approval for the company's therapy.

11 Nov 2022 - K2fly Limited (ASX:K2F) CEO Nic Pollock discusses K2F's progress and milestones over the past year.

04 Nov 2022 - Chimeric Therapeutics Limited (ASX:CHM) CEO and Managing Director Jennifer Chow discusses the company's new agreement with Case Western Reserve University.

03 Nov 2022 - Antisense Therapeutics Limited (ASX:ANP) Chair, Dr Charmaine Gittleson, and new Chief Commercial Officer, Dr Anthony Filippis, discuss Antisense's progress, attracting new talent to the company, and what drew Dr Filippis to the role.

02 Nov 2022 - Novonix Limited (ASX:NVX) CEO Dr Chris Burns discusses news following the company's AGM, including the appointment of new directors and the expansion of the company's development capabilities.

31 Oct 2022 - Shaw and Partners Chief Investment Officer Martin Crabb discusses the market outlook, giving general advice on investment implications.

27 Oct 2022 - icetana Limited (ASX:ICE) CEO and Managing Director Matt Macfarlane discusses the company's recent deal with Japanese group Macnica and the launch of a new product.